anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
In this open-label pilot study, an initial patient, which presented with IPT and SRN, was treated with promising success and five additional patients were then recruited. So this is a report on six eyes of the first six patients with this disease who presented in our practice. The Food and Drug Administration (FDA) granted our site permission to enroll these patients. While anecortave acetate has not yet been approved by the FDA, it has been used in phase 2/3 trials for the treatment of AMD. An informed consent was obtained from each patient. IRB approval was obtained from Manhattan Eye, Ear, and Throat Hospital.

Patients received a posterior juxtascleral injection of 15 mg of anecortave acetate delivered adjacent to the macula using the specially designed curved cannula by Alcon, Inc. Visual acuity (VA) and intraocular pressure (IOP) were measured on each study visit. Fluorescein angiography was used to complement the standard clinical biomicroscopic examination of the macula at baseline and at 3 months intervals. On the first day post-injection, patients had an additional ophthalmic examination including VA testing, biomicroscopy, and IOP measurement.

A 6-month retreatment interval was established for this study based on laboratory data demonstrating that anecortave acetate administered as a slow-release depot adjacent to the posterior scleral surface provided therapeutic drug levels in the adjacent choroid and retina for up to 6 months (9). If patients were clinically unstable or unimproved six months after enrollment, they were offered thermal laser treatment or photodynamic therapy (PDT) in conjunction with the anecortave acetate injection. Patients who were unstable as early as 3 months after enrollment were offered the option to be treated with either thermal laser or PDT. This did not disqualify them from being eligible for the repeat anecortave acetate injection at month 6.
All lower extremities will be exsanguinated by elevation for 2 minutes. For lower extremities in the tourniquet group (TQT), a pneumatic tourniquet will be inflated according to standard practice (\>200 mmHg). For the NOTQT group, the tourniquet will only be inflated during component cementation. In both groups, tourniquet will be deflated after bone cement has set. In both groups, electrocautery will be used as needed throughout the procedure.
OBJECTIVE: Neonatal sepsis and familial hemophagocytic lymphohistiocytosis (fHLH) have similar clinical and laboratory symptoms and the possibility of overlooking fHLH diagnosis is high in newborns with sepsis. History of consanguineous marriage and/or sibling death, hepatomegaly/splenomegaly, and hyperferritinemia (>500 ng/mL) are likely to support fHLH in newborns with sepsis. Therefore, in newborns with sepsis in whom at least 2 of these 3 criteria were detected, genetic variants was investigated for the definitive diagnosed of fHLH. According to the results of genetic examination, we investigated whether these criteria supporting fHLH could be used as a screening test in fHLH.
MATERIALS AND METHODS: fHLH-associated genetic variants were investigated in 22 patients diagnosed with neonatal sepsis who fulfilled at least 2 of the following criteria (1) history of consanguineous marriage and/or sibling death, (2) hepatomegaly/splenomegaly, and (3) hyperferritinemia (>500 ng/mL).
RESULTS: Heterozygous variants were determined in 6 patients (27.2%): 3 STXBP2 , 1 STX11 , 1 UNC13D , and 1 PRF1 . Polymorphisms associated with the clinical symptoms and signs of HLH were determined in 5 patients (22.7%): 4 UNC13D , 1 PRF1 . Two patients were in the heterozygous variants and polymorphism associated with the clinical symptoms and signs of HLH groups. In 12 patients, benign polymorphisms were detected in STXBP2 and UNC13D genes. No change in fHLH associated genes were found in 1 patient.
CONCLUSION: Some variants and/or polymorphisms identified in our patients have been previously reported in patients with HLH. Therefore, we recommend further investigation of fHLH in patients with neonatal sepsis who fulfill at least 2 of the above 3 criteria.
The basic formulation to eradicate mold is a solution of 4 ounces of the essential oil of thyme mixed with one gallon of water. The mixture is sprayed, with a diffuser, into a room of a dwelling. The solution is misted over all surfaces. AC outlet vents are similarly sprayed. The AC inlet vent is also sprayed when the AC is turned ON. Preferably, the dwelling is tented and a small positive air pressure is maintained in the dwelling for 24 hours. The treatment is repeated with an enhanced solution of 4 oz. of essential oils mixed with one gallon of water. The mixture of essential oils is 50% by volume of thyme essential oil and the remaining 50% is equal parts of the essential oils of: cajeput, cedarwood, citronella, clove, cypress, fir-needle, eucalyptus, garlic, lavender, lemon, lemongrass, marjoram, niaouli, onion, orange, oregano, patchouli, peppermint, rosemary, rosewood, tea tree, y-lang and vetivert.
Patient will use venturi or reservoir mask with FiO2 enough to achieve SpO2\>90%. If needed, morphine is titrated to reduce a patient's dyspnoea score by at least one point on the Borg scale and to achieve at least level 5 or less. Initial dose: 10 mg, repeated every 4h until the desired reduction in dyspnoea is obtained. In the case of refractory dyspnoea, the dose is increased by 50%.
The composition according to the invention essentially comprises: 10 to 20 g of glucose, 10 to 40 g of sucrose, 5 to 40 mequiv. of citrate, 20 to 75 mequiv. of chloride, 0 to 50 mequiv. of potassium and 40 to 75 mequiv. of sodium, the respective amounts of the constituents in the indicated ranges being such that a solution of the mixture in one litre of water has an osmolarity of 280 to 320 m.osmol. Advantageously, this composition, in the form of a powder, is provided in sachets containing the required amount for preparing a 220-ml feeding bottle. Use for the oral rehydration of infants suffering from gastroenteritis, especially of viral origin.
This 6-month intervention includes the use of three components: WW's mobile app, virtual workshops, and a private online community. The WW Program involves: self-monitoring of weight, dietary intake, and physical activity; making dietary changes; increasing physical activity; shifting to a more helpful mindset; and learning behavioral strategies to manage these goals. Each week, participants will set goals and weigh-in with a coach via virtual workshop. Participants will be encouraged to use the app and private online community daily and attend weekly virtual workshops. The weekly virtual workshop led by a trained WW Coach features a behavior change technique and enables the participant to practice it to support their goals. These are actionable techniques and strategies that are grounded in scientific research.
Tweets in English from Twitter and posts from weico from 2015 to 2022 for all vaccines. The investigators only included posts from individual accounts and excluded those from news, organizational accounts, or verified users.
PURPOSE:To obtain an antithrombotic agent, containing a 3-butenoic acid derivative or its salt as an active ingredient, having excellent antithrombotic actions and useful for preventing and treating cardiac infarction, etc. CONSTITUTION:This antithrombotic agent contains a compound expressed by the formula (ring A is a tri-lower alkoxyphenyl; either of R<1> and R<2> is a lower alkoxy and the other is amino) or its salt as an active ingredient. The compound expressed by the formula has excellent promoting actions on the activity of plasminogen activators and inhibiting actions on the activity of plasminogen inhibitor-1 and is capable of manifesting excellent antithrombotic actions by either of the oral and parenteral administrations. Methyl (E)-2-[ (E)-3,4,5- trimethoxybenzyl idene]-3-carbamoyl-4-phenyl-3-butenoate is exemplified as the compound expressed by the formula. The daily dose thereof is 0.1-100mg/kg in the case of the oral administration and 0.01-10mg/kg in the case of the parenteral administration. The agent is useful for preventing and treating cardiac infarction, cerebral apoplexy, pulmonary embolism, deep venous thrombosis, peripheral arterial obstruction, angina pectoris, disseminated intravascular coagulation, venous occlusion, diabetic complications, etc.
A system for promoting physical activity for video game players. A video game player wears an article of footwear with a physical activity monitor or “game pod” mounted thereon while exercising or performing some other type of physical activity. The game pod measures the amount of the player's physical activity, and records that amount in a memory. When the player desires to play a video game according to the invention, the player disengages at least the memory from the article of footwear, and then engages the memory with the computer hosting the video game through a computer interface. The computer then obtains the recorded amount of physical activity, and provides a computer function associated with the recorded amount of physical activity. The computer function may include the initiation of the video game itself, the instantiation of a specified gaming environment within the video game, the instantiation of one or more specified characteristics for the player's avatar within the video game, a lengthened playing time for the user's avatar, allowing the player to access data associated with the video game, or a combination of two or more of these functions.
FIELD: medicine; cardiac surgery. SUBSTANCE: vascular complex is taken, prepared, treated with antibiotic agents such as cephotaxim mixed with hentamicin sulfate (8- 9:1-2), and added to medium for storage. Prior to and in the course of preparation the vascular complex is exposed to a reagent containing the hematin chloride-peptide complex such as Aminokrovin. The antibiotic treatment is done as the product is added to the medium containing the hematin chloride-peptide complex with osmolarity 550-600 mmol/kg. It is also expedient to supplement the antibiotic mixture with an effective antimycotic dose of amphotericin B, and the optimum ratio of the mixture of cephotaxim, hentamicin sulfate and amphotericin B is 40-43:5-8:1-2. The storage medium has Aminokrovin as a source of salts and nutrients, and it contains additional cephotaxim and hentamicin sulfate (g/l, 25.0+/- 2.5 and 4.0+/-0.4 respectively). It is expedient to add additional amphotericin B (1.0+/-0.1 g/l). EFFECT: self-regulation of system of protection of vascular tissue exposed to adverse chemical and mechanical factors.
Disclosed is a mucoadhesive nanoparticle delivery system for delivering an immunosuppressant, such as cyclosporine A, to a mucosal site for treatment of a disease or condition involving inflammation or excess immune activity. The system comprises nanoparticles formed from a plurality of linear amphiphilic block copolymers, each having a hydrophobic block comprising polylactide (PLA) and a hydrophilic block comprising dextran. The nanoparticles are surface-functionalized with a mucosal targeting moiety, such as a phenylboronic acid derivative, for targeted delivery and enhanced retention at the mucosal site. Pharmaceutical compositions, methods, and uses thereof comprising the mucoadhesive nanoparticle delivery system are disclosed. The compositions can be administered in an effective amount for treating the disease or condition while substantially preserving or restoring the function and/or integrity of the mucosal lining. The composition may be formulated as an aqueous suspension for administration to an anterior surface of the eye in the treatment of dry eye syndrome.
PROBLEM TO BE SOLVED: To obtain an agent for cleaning living environment from bamboo, always readily available, in the form of a solution of the bamboo extract in ethanol in a specific concentration, thus easy to handle, safe and excellent in cleaning performance. SOLUTION: A bamboo, preferably a species of thick-stemmed bamboo; Phyllostachys pubescens, is, when necessary, crushed, dried and dry-distilled under reduced pressure to collect the distillate of bamboo. This distillate is dissolved in an aqueous ethanol (ethanol content is >=50wt.%, particularly 50-70wt.% is suitable) and the obtained composition is contained in a sprayable vessel or processed to a wet tissue type. The conditions of the reduced pressure is <=10mmHg, particularly 15-45mmHg, for example, in case that the pressure is 20mmHg, the temperature is set to around 300 deg.C. This cleaning agent is sprayed, for example, in rooms, cars, warehouses or pet houses, or sprayed to beds, carpets, mats, clothes, bags and pouches, or applied to human skins, hand strap, door handles, and handrails.  When food products are sprayed with the cleaning agent, they are kept fresh for a prolonged time and hygienic because it has antiseptic action.
Patients with CHF will be considered for inclusion in the study based on their verified medical record, indicating that they are diagnosed with CHF and are using guideline-directed medical therapy (GDMT). Diagnostic criteria, as laid out in the latest 2021 European Society of Cardiology (ESC) guidelines for the diagnosis and management of chronic and acute heart failure, will be followed.
OBJECTIVE: The goal of this study was to investigate the potential protective effect of L-carnitine (20 mg/kg bw, 1/20 LD 50) against aluminum chloride (AlCl3) on the quality of the male rats' testicles and sperm, as well as to determine whether or not the effects of AlCl3 could be counteracted by using L-carnitine as an antioxidant.
MATERIALS AND METHODS: Six groups of 36 adult male albino rats (n=6) were randomly formed. In Group I (Gp I), saline injection was given orally as a control. Group II (Gp II) was injected orally with 75 mg/kg body weight of L-carnitine. Group III (Gp III) was given a high dose of L-carnitine (150 mg/kg body weight) orally, while Group IV (G IV) was given a low dose of AlCl3 (20 mg/kg body weight). Group V (Gp V) was given an oral injection of AlCl3 (20 mg/kg) and L-carnitine (75 mg/kg body weight). Group VI (Gp VI) was given AlCl3 at a dose of 20 mg/kg and L-carnitine at a dose of 150 mg/kg body weight for 60 days. The reproductive capacity of each group was assessed. Thus, in addition to histopathological analysis and the comet assay to evaluate sperm DNA deterioration, final body weight, testicular weight change, and sperm analysis were carried out.
RESULTS: The findings revealed that AlCl3 caused a significant decrease in final body weight, relative weight of sex organs, sperm concentration, motility and viability, serum testosterone concentration, and a significant increase in sperm abnormalities. Furthermore, AlCl3 caused visible changes in the histological structure of the testis.
CONCLUSIONS: L-carnitine treatment alleviated the harmful effects of AlCl3, as evidenced histopathologically by a noticeable improvement in testis tissues. When it comes to treating AlCl3-induced reproductive toxicity in male rat testes, L-carnitine shows promise.
Serious dermatologic reactions including Stevens-Johnson Syndrome (SJS) and toxic epidermal necrolysis (TEN) have been reported in association with eslicarbazepine acetate use. Serious and sometimes fatal dermatologic reactions, including TEN and SJS, have also been reported in patients using oxcarbazepine or carbamazepine which are chemically related to eslicarbazepine acetate. The reporting rate of these reactions associated with oxcarbazepine use exceeds the background incidence rate estimates by a factor of 3- to 10-fold. The reporting rates for eslicarbazepine acetate have not been determined.   
Risk factors for the development of serious and potentially fatal dermatologic reactions with eslicarbazepine acetate use have not been identified.   
If a patient develops a dermatologic reaction while taking eslicarbazepine acetate, discontinue eslicarbazepine acetate use, unless the reaction is clearly not drug-related. Patients with a prior dermatologic reaction with oxcarbazepine, carbamazepine, or eslicarbazepine acetate should ordinarily not be treated with eslicarbazepine acetate [see Contraindications ( 4)] .
OBJECTIVES: I. Evaluate the effectiveness of daily oral pilocarpine versus placebo in relieving dry mouth due to the ongoing use of an opioid for cancer related pain at 2 weeks by comparing proportion of patients with at least one response during the 2 week period, time of first response, and duration of first response. II. Evaluate the adverse effects of pilocarpine in these patients. III. Evaluate whether constipation, sedation, poor appetite, and nausea are ameliorated by pilocarpine in these patients. IV. Evaluate the effect of pilocarpine on quality of life of this patient group. V. Determine the timing and duration of the effect of pilocarpine in this patient population.

OUTLINE: This is a randomized, double-blind, multicenter study. Patients receive either oral pilocarpine four times daily (arm I) or oral placebo four times daily (arm II) for 4 weeks. At the end of the 4 weeks, all patients are given the option to receive oral pilocarpine. Quality of life is assessed 2 days prior to randomization, after 2 weeks of treatment, and after 4 weeks of treatment.

PROJECTED ACCRUAL: There will be 60 patients accrued into this study within 18 months.
FIELD: molecular biology, veterinary science. SUBSTANCE: invention relates to method that can be used for detection of cattle viral diarrhea. Method involves synthesis of oligonucleotide primers 5'-TAG-ATT-CCA-GAC-CGA-CCC-3' and 5'-GGA-AGG-GAT-ACA-ACG-GGC-3' and synthesis of complementary DNA on DNA matrix. Then amplification of synthesized DNA is carried out by method of polymerase chain reaction and polymerase chain reaction products size is analyzed. Proposed method ensures to differentiate cattle viral diarrhea virus from the close-related classical porcine plague virus. EFFECT: improved method of virus detection. 1 tbl, 1 ex
An aqs. product for the care of the mouth and teeth contng. Bacillus subtilis protease. Compared with fungal or pancreatic enzymes, the above protease is toxicologically innocuous and more stable in toothpastes. Inhibits the formn. of hard or soft deposits on the teeth and prevents parodontal diseases. The product, e.g. a toothpaste, contains the usual adjuvants and excipients together with Bacillus subtilis protease (0.2-5 Anson units/g) in an amount of 0.05-10% by wt., pref. 0.25-2.5%. Optionally, a fluorine cpd., pref. water-sol., may be added in an amount is not > 2% by wt.
There are three components to this study: (1) the prospective, randomized, controlled trial (RCT), which includes a pharmacist-led hospital discharge care intervention, (2) the qualitative study, which involves focus groups and interviews, and (3) a cost-effectiveness study, which involves a review of the literature and a time-and-motion study component.For all three studies, there are two sites: CSMC and Brigham and Women's Hospital in Boston. Additionally, Dr. Kennelty of University of Iowa will participate in the qualitative study.1. For the RCT: Eligible patients will be identified through the use of a daily Epic report using inclusion/exclusion criteria. Patients will be randomized by a study coordinator to the intervention arm or control arm. For the control arm, patients will receive usual care, which includes medication reconciliation at hospital admission. For the intervention arm, pharmacy staff will address medication reconciliation at hospital discharge, medication review, and medication adherence. Most intervention activities will occur during the hospital stay or during a post-discharge phone call. We estimate a total number of 4,888 patients per study arm.

2. For the qualitative study: This is a qualitative study employing focus groups aimed at understanding implementation barriers and facilitators. Dr. Kennelty and study staff will conduct 3-day site visits to hold focus groups and/or interviews regarding intervention expectations, how the intervention is being implemented, barriers/facilitators to adoption and implementation, and adaptations made during delivery. Towards the end of the trial, Dr. Kennelty and study staff will use phone interviews to determine any changes to the implementation of PHARM-DC that occurred during the RCT, as well as to understand whether and how institutions will address the maintenance of PHARM-DC after the study ends. We estimate that up to 180 people may participate in this qualitative study.

3. For the cost-effectiveness study: This is a time-and-motion study aimed at understanding how much time during the day pharmacists spend on activities related to the hospital discharge (and post-discharge) interventions. During the trial, we will use time and motion methodology to understand how much pharmacist time is needed for PHARM-DC. Coupled with data on post-discharge utilization, this will enable us to conduct economic analyses.
Participants in the intervention group will perform a twelve-week training intervention in addition to their usual care (as provided by the (memory) clinics where the patients are recruited). The training intervention will be prescribed according to our newly developed exergame-based training concept (called 'Brain-IT' exergame-based training concept). Our complete 'Brain-IT' exergame-based training concept has recently been published including sufficient details about the exergame components as well as the exercise and training characteristics (i.e. including all predefined levels of task demands as well as the detailed progression rules) to allow full replication (i.e. consider supplementary file 3 of doi: 10.3389/fnagi.2021.734012). This training concept was planned and will be reported using the Consensus on Exercise Reporting Template (CERT; doi: 10.1136/bjsports-2016-096651).
Viral infections are a major source of morbidity and mortality in the context of immune deficiency and immunosuppression following allogeneic hematopoietic cell (allo-HCT) and solid organ transplantation (SOT). The pharmacological treatment of viral infections is challenging and often complicated by limited efficacy, the development of resistance, and intolerable side effects. A promising strategy to rapidly restore antiviral immunity is the adoptive transfer of virus-specific T cells (VST). This therapy involves the isolation and ex vivo expansion or direct selection of antigen-specific T cells from healthy seropositive donors, followed by infusion into the patient. This article provides a practical guide to VST therapy by reviewing manufacturing techniques, donor selection, and treatment indications. The safety and efficacy data of VSTs gathered in clinical trials over nearly 30 years is summarized. Current challenges and limitations are discussed, as well as opportunities for further research and development.